Kelly KR - Search Results

1

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.

Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS. Visconte V, et al. Among authors: kelly kr. Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15. Leukemia. 2016. PMID: 26369982 Free PMC article. No abstract available.

2

Emerging drugs in the treatment of pancreatic cancer.

Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Mahalingam D, et al. Among authors: kelly kr. Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502. Expert Opin Emerg Drugs. 2009. PMID: 19466902 Review.

3

Reovirus-based therapy for cancer.

Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Kelly K, et al. Expert Opin Biol Ther. 2009 Jul;9(7):817-30. doi: 10.1517/14712590903002039. Expert Opin Biol Ther. 2009. PMID: 19527106 Review.

4

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Carew JS, et al. J Cell Mol Med. 2010 Oct;14(10):2448-59. doi: 10.1111/j.1582-4934.2009.00832.x. J Cell Mol Med. 2010. PMID: 19583815 Free PMC article.

5

Cdc7 kinase - a new target for drug development.

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Swords R, et al. Eur J Cancer. 2010 Jan;46(1):33-40. doi: 10.1016/j.ejca.2009.09.020. Eur J Cancer. 2010. PMID: 19815406 Review.

6

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Mahalingam D, et al. Among authors: kelly kr. Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028765

7

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Swords RT, et al. Among authors: kelly kr. Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4. Blood. 2010. PMID: 20203261 Free article.

8

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.

Kelly K, Swords R, Mahalingam D, Giles FJ. Kelly K, et al. Leuk Lymphoma. 2010 Aug;51(8):1399-413. doi: 10.3109/10428194.2010.491135. Leuk Lymphoma. 2010. PMID: 20528247 Review.

9

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.

Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. Kelly KR, et al. J Cell Mol Med. 2011 Oct;15(10):2057-70. doi: 10.1111/j.1582-4934.2010.01218.x. J Cell Mol Med. 2011. PMID: 21091633 Free PMC article.

10

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.

Carew JS, Espitia CM, Esquivel JA 2nd, Mahalingam D, Kelly KR, Reddy G, Giles FJ, Nawrocki ST. Carew JS, et al. Among authors: kelly kr. J Biol Chem. 2011 Feb 25;286(8):6602-13. doi: 10.1074/jbc.M110.151324. Epub 2010 Dec 10. J Biol Chem. 2011. PMID: 21148553 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters